PCSK9 Turning Point? Sanofi/Regeneron Dangle Lower Price Carrot For Praluent
Executive Summary
ODYSSEY outcomes study homes in on value of PCSK9 inhibition for the subgroup of patients with LDL of at least 100 mg/dL, a potentially large market, but how much will payers ease restrictions in exchange for a lower price?